Prevention of hepatocellular carcinoma: The holy grail of hepatitis B treatment

Journal of Hepatology

Volumn 50, Issue 5, 2009, Pages 854-856

  Sherman, Morris ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; EDITORIAL; GENERAL PRACTITIONER; HEPATITIS B; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RISK REDUCTION; SCREENING TEST; VIRUS LOAD;

AGE FACTORS; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER; LIVER NEOPLASMS; VIRAL LOAD;

EID: 64549110662     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.02.005     Document Type: Editorial

References (19)

1. Robotin M.C., Kansil M., Howard K., George J., Tipper S., Dore G.J., et al. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol 50 (2009) 990-998
2. Bruix J., and Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
3. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
4. European Association for Study of the Liver. EASL clinical practice guidleines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
5. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
6. Prati D., Taioli E., Zanella A., Della Torre E., Butelli S., Del Vecchio E., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
7. Kim H.C., Nam C.M., Jee S.H., Han K.H., Oh D.K., and Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 328 (2004) 983
8. Yuen M.F., Yuan H.J., Wong D.K., Yuen J.C., Wong W.M., Chan A.O., et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54 (2005) 1610-1614
9. Yang H.I., Lu S.N., Liaw Y.F., You S.L., Sun C.A., Wang L.Y., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347 (2002) 168-174
10. Gish R.G., Lok A.S., Chang T.T., de Man R.A., Gadano A., Sollano J., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133 (2007) 1437-1444
11. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359 (2008) 2442-2455
12. Chen G., Lin W., Shen F., Iloeje U.H., London W.T., and Evans A.A. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol 34 (2005) 132-137
13. Yu M.W., Yeh S.H., Chen P.J., Liaw Y.F., Lin C.L., Liu C.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97 (2005) 265-272
14. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
15. Yuen M.F., Seto W.K., Chow D.H., Tsui K., Wong D.K., Ngai V.W., et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 12 (2007) 1295-1303
16. Rapti I., Dimou E., Mitsoula P., and Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45 (2007) 307-313
17. Di Marco V., Marzano A., Lampertico P., Andreone P., Santantonio T., Almasio P.L., et al. Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40 (2004) 883-891
18. Tong M.J., Hsien C., Hsu L., Sun H.E., and Blatt L.M. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 48 (2008) 1070-1078
19. Stravitz R.T., Heuman D.M., Chand N., Sterling R.K., Shiffman M.L., Luketic V.A., et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 121 (2008) 119-126